Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 70 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| AlloVir Inc | ALVR | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.78 | 04:05:52 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.78 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 2 | 70 | - | 0.6231 - 6.12 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 04:00:00 | 18 | $ 0.766 | USD |
AlloVir Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 88.97M | 114.06M | - | 0 | -190.42M | -1.67 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
AlloVir News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALVR Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.7527 | 0.825 | 0.7345 | 0.7595307 | 294,531 | 0.0273 | 3.63% |
| 1 Month | 0.74 | 0.85 | 0.7057 | 0.7712816 | 543,238 | 0.04 | 5.41% |
| 3 Months | 0.7236 | 0.85 | 0.6425 | 0.7316732 | 644,572 | 0.0564 | 7.79% |
| 6 Months | 1.43 | 2.485 | 0.6231 | 0.9474434 | 1,407,577 | -0.65 | -45.45% |
| 1 Year | 3.62 | 6.12 | 0.6231 | 1.66 | 1,060,026 | -2.84 | -78.45% |
| 3 Years | 22.55 | 26.41 | 0.6231 | 4.93 | 673,980 | -21.77 | -96.54% |
| 5 Years | 22.82 | 48.96 | 0.6231 | 7.91 | 608,834 | -22.04 | -96.58% |
AlloVir Description
| AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. |
